All In Biotech

Drug Trial Radar · NCT07100080

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 661 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

661

Planned (sponsor's estimate)

Start

Nov 5, 2025

Primary completion

Dec 15, 2028

Study completion Nov 15, 2030

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study of Izalontamab Brengitecan (BMS-986507) versus platinum-based chemotherapy with or without Amivantamab for EGFR-mutated non-small cell lung cancer after failure of EGFR TKI therapy

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • Iza-brenDrug

    Specified dose on specified days

  • CarboplatinDrug

    Specified dose on specified days

  • CisplatinDrug

    Specified dose on specified days

  • PemetrexedDrug

    Specified dose on specified days

  • AmivantamabDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase 3 Dose (RP3D) of BMS-986507Time frame: Approximately 3 months after the first dose
  2. Progression-Free Survival (PFS) Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)Time frame: Up to 3 years

Locations

187 sites in 25 countries. Site status is shown where the registry gives one.

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building

    Irvine, California · Recruiting

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center

    Orange, California · Recruiting

  • Shaw Cancer Center

    Edwards, Colorado · Recruiting

  • Local Institution - 0085

    Gainesville, Florida · Withdrawn

  • Local Institution - 0142

    Pembroke Pines, Florida · Not yet recruiting

  • Piedmont Healthcare

    Atlanta, Georgia · Recruiting

  • John B Amos Cancer Center

    Columbus, Georgia · Recruiting

  • Rush University Medical Center

    Chicago, Illinois · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Renown Regional Medical Center

    Reno, Nevada · Recruiting

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island

    Mineola, New York · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Weill Cornell Medical College

    New York, New York · Recruiting

  • Rochester General Hospital Infectious Disease

    Rochester, New York · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C

    Columbus, Ohio · Recruiting

  • Providence Cancer Institute Franz Clinic

    Portland, Oregon · Recruiting

  • Providence St. Vincent Medical Center

    Portland, Oregon · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • West Penn Allegheny Health

    Pittsburgh, Pennsylvania · Recruiting

  • Local Institution - 0268

    Chattanooga, Tennessee · Withdrawn

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Local Institution - 0173

    San Antonio, Texas · Not yet recruiting

  • University of Virginia Health System

    Charlottesville, Virginia · Recruiting

  • Virginia Commonwealth University (Vcu)

    Richmond, Virginia · Recruiting

  • Hospital Privado Universitario de Córdoba

    Córdoba, Argentina · Recruiting

  • Instituto Alexander Fleming

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Hospital Italiano de Buenos Aires

    ABB, Buenos Aires F.D., Argentina · Recruiting

  • Local Institution - 0280

    Wilrijk, Antwerpen, Belgium · Not yet recruiting

  • Local Institution - 0161

    Auderghem, Bruxelles-Capitale, Région de, Belgium · Not yet recruiting

  • Local Institution - 0022

    Yvoir, Namur, Belgium · Not yet recruiting

  • Local Institution - 0023

    Ghent, Oost-Vlaanderen, Belgium · Not yet recruiting

  • Local Institution - 0024

    Sint-Niklaas, Oost-Vlaanderen, Belgium · Not yet recruiting

  • Arthur J. E. Child Comprehensive Cancer Centre

    Calgary, Alberta, Canada · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • Local Institution - 0184

    Chicoutimi, Quebec, Canada · Not yet recruiting

  • Local Institution - 0185

    Montreal, Quebec, Canada · Withdrawn

Showing 40 of 187 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.